Can Neuropathy Be Reversed With Stem Cells? What Is Known and What Is Not

Written by Dr. Joel Cherdack, Founder, Houston Regenerative Medicine

The honest answer is no, not in the way the word “reversed” suggests, and you should be careful with any clinic that tells you otherwise.

That is not the same as saying nothing can be done. Symptoms can change. Function can change. But “reversed” implies damaged nerve returned to its original state on a predictable schedule, and there is no clinic in Houston or anywhere else that can promise you that. If you have been quoted a success rate for neuropathy, ask what study it came from and read the study.

This page explains what is actually understood about nerve damage and regenerative approaches, where the uncertainty sits, and what to ask before you spend money on any of it.

This is general information, not medical advice, and it does not replace evaluation by a licensed clinician.

Why “reversed” is the wrong word for nerve damage

Peripheral nerves are not all one thing, and that is the reason the question has no clean yes.

A nerve fiber has an axon, the long projection that carries the signal, and in many nerves a myelin sheath insulating it. Damage can affect the myelin, the axon, or the nerve cell body itself, and those three situations behave very differently. Damage limited to myelin has more capacity to improve than damage to the axon. Loss of the nerve cell body is a different matter again.

Peripheral nerve does have some regenerative capacity, unlike nerve in the brain and spinal cord. That capacity is slow, and it depends heavily on whether the structure the nerve regrows along is still intact. It also declines with age and with the conditions that caused the damage in the first place.

So the useful question is not “can it be reversed”. It is “what is damaged, how badly, how long has it been that way, and is the thing causing the damage still happening?”

What is causing your neuropathy matters more than the treatment

This is the part that gets skipped in marketing, and it is the part that changes outcomes.

Peripheral neuropathy is a description of a problem, not a diagnosis. Diabetes is one of the biggest drivers of it: the National Institute of Diabetes and Digestive and Kidney Diseases states that up to one half of people with diabetes have peripheral neuropathy, and that over time high blood glucose and high blood fats from diabetes can damage nerves and the small blood vessels that feed them [1]. Where diabetes is the cause, glucose control addresses the thing doing the damage, which is why it belongs at the center of the plan. Chemotherapy-induced neuropathy behaves differently. So do neuropathies driven by B12 deficiency, thyroid disease, alcohol use, autoimmune conditions, nerve compression and inherited disorders. Some have specific treatments that address the cause directly.

A clinic that does not ask what is causing your neuropathy before proposing a treatment for it is not evaluating you. It is selling you something.

If the underlying driver is still active, any intervention is working against an ongoing process. That is worth understanding before you weigh the cost of anything.

What regenerative approaches are actually aiming at

Where regenerative medicine is being explored for neuropathy, the proposed mechanisms are less dramatic than the marketing suggests. The interest centers on the local environment around damaged nerve: inflammation, blood supply to the nerve, and the signalling molecules that influence whether tissue repairs or continues to degrade.

That is a meaningfully different claim from regrowing a destroyed nerve. Improving the conditions around a struggling nerve and rebuilding one that is gone are not the same proposition, and the distinction is where a lot of overpromising happens.

Where the evidence stands: research in this area is ongoing and much of it is early. Findings in laboratory and animal models do not automatically translate to people, published human studies vary widely in size and quality, and results reported for one type of neuropathy do not transfer to another. Anyone presenting this as settled is ahead of the evidence.

This is also why regulatory framing matters. Therapies using a patient’s own minimally manipulated cells for homologous use fall under FDA 21 CFR Part 1271. They are regulated, and that is not the same thing as being approved as a drug for treating neuropathy. Any clinic telling you this is FDA approved for your condition is telling you something that is not accurate.

The distinctions that decide what the conversation is even about

This is where a general article has to be careful, because what could change in any individual case depends on facts about that person that only an examination produces. What can be set out is which distinctions matter, so you know what to ask about.

How long the symptoms have been present, and how far they have progressed. The earlier section on myelin, axons and nerve cell bodies is the reason this matters. Those are different situations with different amounts of room in them, and which one applies to you is a clinical question.

Whether the underlying driver is under control. If something is still actively damaging the nerve, that is a separate problem from anything injected, and it does not go away on its own.

Which symptom you are actually asking about. Numbness and pain do not necessarily move together. Some people describe a change in burning or electrical pain without a change in numbness, and improvement in one is not evidence of repair in the other. Be specific about which one matters most to you, because “did it work” is not one question.

What is not addressed at all: the underlying disease. A regenerative procedure does not treat your diabetes, your thyroid, your B12 level or your chemotherapy history. That is worth stating plainly, because it is the gap people most often do not realize is there.

Questions worth asking any Houston clinic before you commit

Take these to a consultation. The answers tell you a great deal about who you are dealing with.

1. What do you think is causing my neuropathy, and how did you determine that? If nobody has investigated the cause, stop there.
2. What specifically is being injected, and what is the regulatory status of that product? You are entitled to a plain answer.
3. What outcome measure will you use, and when will it be assessed? A clinic tracking outcomes can tell you how it measures them.
4. What would tell us this is not working, and at what point would you say so? A defined stopping point is a good sign.
5. What does the full course cost, including any follow-up you would recommend? Get it in writing before you start.
6. Can you show me the research you are basing this on? Then read it, including how many people were in it.

If a clinic answers a question about evidence with a testimonial, that is your answer.

What a straight answer sounds like

Nobody can tell you your neuropathy will be reversed, and a clinic that says otherwise is telling you something it cannot know.

What a careful assessment of neuropathy generally works through is what is driving the symptoms, how long they have been present, what has already been tried, and whether the thing causing the damage is still active. Only after that does the question of what to do about it become answerable.

Sometimes the answer that follows is that a regenerative approach is not the right route, and that you would be better served by a neurologist, by better control of an underlying condition, or by a treatment specifically indicated for your type of neuropathy. You are entitled to hear that, and hearing it is a sign you are somewhere careful.

Watch the video or listen to the podcast

Talk to someone about your symptoms

If you want an assessment that starts with what is causing your neuropathy, that is the conversation to have.

See our neuropathy treatment page for more on how we approach evaluation.

Houston Regenerative Medicine, 100 Glenborough Dr, Suite 0403j, Houston, TX 77067. Call (346) 581-1547 to ask what an evaluation involves.

If you have sudden weakness, rapidly worsening numbness, loss of bladder or bowel control, or a foot wound that is not healing, seek medical care promptly instead of booking a routine appointment.

This content is provided for general informational purposes only and is not medical advice. It does not create a doctor-patient relationship and it is not a substitute for evaluation and diagnosis by a licensed clinician. Individual results vary and no outcome is promised. Therapies using a patient’s own cells are regulated under FDA 21 CFR Part 1271 and are not FDA-approved drug products for the treatment of peripheral neuropathy.

Sources

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Peripheral Neuropathy. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies/peripheral-neuropathy. Accessed 3 September 2026.